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The complexity of the living cell is supported by the 
multitasking activity of its protein constituents. The 
kinase Ataxia Telangiectasia Mutated (ATM) is a clear 
example. Not only does it orchestrate the DNA damage 
response but also sustains cellular homeostasis, 
including metabolism, control of oxidative stress, 
autophagy and apoptosis [1]. Given its prevalent role in 
the cellular response to various forms of stress, it is not 
surprising that mutations that inactivate ATM occur in 
~10% of human cancers. The mitogen-activated protein 
kinase (MAPK) ERK5 also presents an obvious 
multitasking activity. Besides being a nodal point to 
growth factor and stress signaling pathways, ERK5 has 
a C-terminus with transcriptional coactivator activity 
[2]. ERK5 mutations in cancer are a rare event, 
however, an increasing body of evidence relates ERK5 
to cancer. ATM can phosphorylate a vast network of 
cellular substrates, but ERK5 is not in the list of close 
relatives. Nevertheless, the two kinases might be closer 
than expected. Atm-/- mice, like humans carrying ATM 
inactivating mutations, are prone to lymphomagenic 
tumors. Recently, we have demonstrated that in absence 
of ERK5 the development of T-cell lymphoma in Atm-/- 
mice is reduced, revealing a functional link between 
ATM and ERK5 [3].  
The loss of ERK5 presents minor effects in T cell 
development in mice [4], whereas the loss of ATM 
profoundly affects it, thanks to ATM's involvement in 
the T-cell receptor (TCR) recombination process and 
repair of unresolved DNA double strand breaks (DSB). 
The recombination of VDJ gene segments of TCR takes 
place in the G1 cell cycle phase of the most immature T 
cells, namely CD4-CD8- double-negative (DN) 
thymocytes, initiated by the lymphocyte-specific 
endonuclease RAG1/2. To prevent cell division in 
thymocytes with unrepaired DSB, ATM activates G1/S 
and G2/M cell cycle checkpoints. However, in absence 
of ATM, the G1/S and G2/M checkpoints are less 
effective, some VDJ DSB escape G1 and evolve into 
chromosomal translocations. The presence of DSB 
activates the phosphorylation of histone H2AX by ATM 
and DNA-dependent protein kinase (DNA-PK). 
Phosphorylation of H2AX is necessary to preserve the 
structural integrity of DNA ends, for proper functioning 
of the G2/M checkpoint and apoptosis in response to 
genomic  stress  [5].  Our  recent  results  show  that  the  
 
 







phosphorylation of H2AX and apoptosis in response to 
DSB are impaired in Atm-/- mice but not in Atm-/-Erk5-/- 
thymocytes, suggesting that ERK5 inhibits H2AX 
phosphorylation in Atm-/- mice [3]. Moreover, Atm-/-
Erk5-/- mice presented a higher percentage of DN 
thymocytes in the G2/M cell-cycle phase. We therefore 
envision a model where the phosphorylation of H2AX 
by DNA-PK in response to unrepaired DSB in 
thymocytes of Atm-/- mice is inhibited by ERK5, thereby 
lessening the G2/M checkpoint and increasing genomic 
instability (Figure 1). In wild type mice, this ERK5 
activity would be under control of ATM in a signaling 



























The delayed death due to T-cell lymphoma 
development in Atm-/-Erk5-/- mice suggests that 
pharmacological targeting of ERK5 has therapeutic 
potential for T-cell lymphoma patients carrying 
inactivating ATM mutations. However, as ERK5 
participates in additional cellular functions, the strategy 
that involves the use of ERK5 inhibitors needs to be 
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Figure 1. A schematic model depicting  the hypothetical  role 
of ERK5 (red bars)  in the cellular response to unrepaired DNA 
damage  in  VDJ  recombination  in  thymocytes.  NHEJ,  non‐
homologous  end‐joining  pathway  of  DSB  repair.  HR, 
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carefully evaluated. For instance, we have recently 
shown that ERK5 modulates the dCTP levels in T cell 
acute lymphoblastic leukemia Jurkat cells treated with 
thymidine, thereby reducing DNA replication stress [6]. 
Therefore, if ERK5 inhibitors are to be used in 
combination with antineoplastic dCTP analogues such 
as cytarabine, the former could counteract the 
therapeutic effect of the latter [7]. The variety of 
cellular functions governed by ERK5 and ATM 
constitute a barrier for therapy, warranting a search for 
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